JP2012529891A5 - - Google Patents

Download PDF

Info

Publication number
JP2012529891A5
JP2012529891A5 JP2012515229A JP2012515229A JP2012529891A5 JP 2012529891 A5 JP2012529891 A5 JP 2012529891A5 JP 2012515229 A JP2012515229 A JP 2012515229A JP 2012515229 A JP2012515229 A JP 2012515229A JP 2012529891 A5 JP2012529891 A5 JP 2012529891A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
chimeric polypeptide
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012515229A
Other languages
English (en)
Japanese (ja)
Other versions
JP6166041B2 (ja
JP2012529891A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/038703 external-priority patent/WO2010148010A1/en
Publication of JP2012529891A publication Critical patent/JP2012529891A/ja
Publication of JP2012529891A5 publication Critical patent/JP2012529891A5/ja
Application granted granted Critical
Publication of JP6166041B2 publication Critical patent/JP6166041B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012515229A 2009-06-15 2010-06-15 ミオチューブラリン１（ｍｔｍ１）ポリペプチドを含むキメラポリペプチドを使用して筋細管ミオパシーを処置するための方法および組成物 Expired - Fee Related JP6166041B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26873209P 2009-06-15 2009-06-15
US61/268,732 2009-06-15
PCT/US2010/038703 WO2010148010A1 (en) 2009-06-15 2010-06-15 Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides

Publications (3)

Publication Number Publication Date
JP2012529891A JP2012529891A (ja) 2012-11-29
JP2012529891A5 true JP2012529891A5 (enExample) 2013-08-01
JP6166041B2 JP6166041B2 (ja) 2017-07-19

Family

ID=43356726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012515229A Expired - Fee Related JP6166041B2 (ja) 2009-06-15 2010-06-15 ミオチューブラリン１（ｍｔｍ１）ポリペプチドを含むキメラポリペプチドを使用して筋細管ミオパシーを処置するための方法および組成物

Country Status (8)

Country Link
US (2) US8834866B2 (enExample)
EP (1) EP2443155B1 (enExample)
JP (1) JP6166041B2 (enExample)
AU (1) AU2010260145B2 (enExample)
BR (1) BRPI1011236A2 (enExample)
CA (1) CA2797480A1 (enExample)
ES (1) ES2630057T3 (enExample)
WO (1) WO2010148010A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148010A1 (en) 2009-06-15 2010-12-23 4S3 Bioscience Inc. Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides
US9701740B2 (en) 2011-04-01 2017-07-11 Yale University Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair
US9610362B2 (en) 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
US9732146B2 (en) 2012-03-30 2017-08-15 The United States Of America As Represented By The Department Of Veterans Affairs Antibody-mediated transduction of heat shock proteins into living cells
WO2013177428A1 (en) * 2012-05-23 2013-11-28 Valerion Therapeutics, Inc. Methods for increasing muscle contractility
WO2014130723A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
US8957044B2 (en) * 2013-03-01 2015-02-17 Wake Forest University Health Sciences Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
FR3004463A1 (fr) * 2013-04-11 2014-10-17 Genethon Systeme d'expression pour une therapie genique selective
CA2936102A1 (en) 2014-01-13 2015-07-16 Valerion Therapeutics, Llc Internalizing moieties
EP3778630A1 (en) * 2014-02-28 2021-02-17 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
EP3154570A4 (en) * 2014-06-13 2017-12-27 Valerion Therapeutics, LLC Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
AU2015308894A1 (en) 2014-08-27 2017-03-23 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
US10383945B2 (en) 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody
EP3471777A1 (en) 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
EP3509614A4 (en) 2016-09-09 2020-04-22 Valerion Therapeutics, LLC METHODS AND COMPOSITIONS FOR THE TREATMENT OF LAFORA DISEASE
EP3648789B9 (en) * 2017-07-03 2023-09-27 Université de Strasbourg Mtmr2-s polypeptide for use in the treatment of myopathies
MX2022002342A (es) 2019-08-30 2022-06-14 Univ Yale Composiciones y metodos para suministro de acidos nucleicos a celulas.
JP2024508309A (ja) * 2021-03-03 2024-02-26 イエール ユニバーシティ 骨格筋疾患を治療するための組成物及び方法
GB202201713D0 (en) * 2022-02-10 2022-03-30 Univ Dundee An affinity directed phosphatase system for targeted protein dephosphorylation
WO2024238807A2 (en) 2023-05-16 2024-11-21 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
US6068829A (en) 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
WO1997032602A1 (en) 1996-03-08 1997-09-12 The Regents Of The University Of California DELIVERY SYSTEM USING mAb 3E10 AND MUTANTS AND/OR FUNCTIONAL FRAGMENTS THEREOF
US6329501B1 (en) 1997-05-29 2001-12-11 Auburn University Methods and compositions for targeting compounds to muscle
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
JPH11151088A (ja) 1997-11-20 1999-06-08 Univ Tokyo 脱リン酸化反応を触媒する新規酵素
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6174687B1 (en) 1999-02-26 2001-01-16 The Burnham Institute Methods of identifying lung homing molecules using membrane dipeptidase
US6303573B1 (en) 1999-06-07 2001-10-16 The Burnham Institute Heart homing peptides and methods of using same
US6551809B2 (en) 2001-03-20 2003-04-22 Applera Corporation Isolated human phosphatase proteins, nucleic acid molecules encoding human phophatase proteins, and uses thereof
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
WO2005115439A2 (en) * 2004-05-27 2005-12-08 Acceleron Pharma Inc. Cerberus/coco derivatives and uses thereof
US20100143358A1 (en) 2007-01-22 2010-06-10 The United States Government As Represented By The Department Of Veterans Affairs Use of Antibody Conjugates
CA2688240A1 (en) 2007-05-24 2008-12-04 The United States Government As Represented By The Department Of Veterans Affairs Intranuclear protein transduction through a nucleoside salvage pathway
WO2010044894A1 (en) 2008-10-15 2010-04-22 4S3 Bioscience Inc. Methods and compositions for treatment of myotonic dystrophy
CA2799608C (en) 2009-05-28 2023-02-28 Richard H. Weisbart Amino acid sequences which enhance peptide conjugate solubility
WO2010148010A1 (en) 2009-06-15 2010-12-23 4S3 Bioscience Inc. Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides
GB2476671B (en) 2010-01-04 2014-11-26 Plastic Logic Ltd Touch-sensing systems
JP5240316B2 (ja) 2010-10-26 2013-07-17 株式会社デンソー 車両乗員非操作運転システム
CN103459572A (zh) 2011-04-05 2013-12-18 雪佛龙奥伦耐有限责任公司 低粘度船用气缸润滑油组合物
WO2013177428A1 (en) 2012-05-23 2013-11-28 Valerion Therapeutics, Inc. Methods for increasing muscle contractility

Similar Documents

Publication Publication Date Title
JP2012529891A5 (enExample)
US11833120B2 (en) Binding protein drug conjugates comprising anthracycline derivatives
CN107849148B (zh) 三特异性结合蛋白质及使用方法
JP4011914B2 (ja) キメラポリペプチド、その製造方法、およびその使用
AU2018362349B2 (en) Improved TfR-selective binding peptides capable of crossing the blood brain barrier
US20180106790A1 (en) Single chain proteins with c-terminal modifications
CN106661128A (zh) 构建氨基末端免疫球蛋白融合蛋白的方法及其组合物
US9474794B2 (en) Antibodies that bind to adrenomedullin and to adrenomedullin receptors and the uses thereof as drugs
US20240279360A1 (en) Bifunctional compounds containing igf-2 polypeptides
JP2020072685A (ja) クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンａ及びトキシンｂに対する四重特異性の八量体型結合剤及び抗体
CN107206103A (zh) 用于治疗目的的抗体‑脲酶缀合物
US20180028682A1 (en) Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
JP2019535645A5 (enExample)
JP2016027801A (ja) 改良された抗血清アルブミン結合変異体
JP2023145635A (ja) 免疫調節特性を有するペプチド
US10072065B2 (en) Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
US20210401927A1 (en) Peptides Having Immunomodulatory Properties
US11952410B2 (en) Mesothelin-targeted trail trimer
US11952402B2 (en) Fusion protein containing trail and IgG binding domain and the uses thereof
CN119613545B (zh) 非天然氨基酸修饰的抗ccl5纳米抗体
CN109641066B (zh) 新的IgG结合肽和含有该肽的多功能抗原结合蛋白
WO2022240407A1 (en) Delivery constructs derived from bacterial toxins and uses thereof
NZ794344A (en) Tgfβr2 extracellular domain truncated molecule, fusion protein of tgfβr2 extracellular domain truncated molecule and anti-egfr antibody, and anti-tumor use of fusion protein